The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, PR China; Shangqiu Medical College, Shangqiu, Henan 476000, PR China.
The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, PR China.
Biomed Pharmacother. 2018 Jan;97:511-517. doi: 10.1016/j.biopha.2017.09.143. Epub 2017 Nov 6.
Recent studies have showed that microRNA-150 (miR-150) is up-regulated in various cancers including cervical cancer. However, the specific mechanism of miR-150 in the regulation of cell proliferation, migration and invasion is still unclear. In this study, a total of 150 cervical cancer samples, including 50 cervical cancer tissues, 50 corresponding adjacent non-neoplastic tissues, and 50 serum samples were collected from cervical cancer patients. 50 matched normal tissues and 50 serum samples were collected from the control group. MiR-150 was evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). Programmed cell death protein 4 (PDCD4) was evaluated by qRT-PCR and western blot. Cell migration and invasion were assessed by transwell assays. Proliferative abilities were determined by MTT assays. Luciferase reporter assay was employed to validate the direct target of PDCD4 by miR-150. We found that miR-150 was increased in cervical cancer specimens. In contrast, PDCD4 was decreased in cervical cancer tissues. MiR-150 promoted cell migration, invasion and proliferation through targeting PDCD4. These results collectively indicated that miR-150 might be used as a potential therapeutic biomarker in cervical cancer.
最近的研究表明，microRNA-150（miR-150）在包括宫颈癌在内的各种癌症中上调。然而，miR-150 调节细胞增殖、迁移和侵袭的确切机制尚不清楚。在这项研究中，共收集了 150 例宫颈癌患者的 50 例宫颈癌组织、50 例相应的癌旁非肿瘤组织和 50 例血清样本，收集了 50 例配对的正常组织和 50 例对照组血清样本。通过定量实时聚合酶链反应（qRT-PCR）评估 miR-150。通过 qRT-PCR 和 Western blot 评估程序性细胞死亡蛋白 4（PDCD4）。通过 Transwell 测定评估细胞迁移和侵袭。通过 MTT 测定确定增殖能力。通过荧光素酶报告基因实验验证 PDCD4 是 miR-150 的直接靶标。我们发现 miR-150 在宫颈癌标本中增加。相比之下，PDCD4 在宫颈癌组织中减少。miR-150 通过靶向 PDCD4 促进细胞迁移、侵袭和增殖。这些结果共同表明，miR-150 可能作为宫颈癌的潜在治疗性生物标志物。
